Research and Markets (http://www.researchandmarkets.com/research/8gwkqg/competitor) has announced the addition of the "Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors" report to their offering.
The present Competitive Intelligence Report about VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) used to treat various cancers and ophthalmic diseases as of November 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The first generation of recombinant antibodies targeting VEGF consists of bevacizumab (Avastin) from Roche (Genentech) and ranibizumab (Lucentis) from Roche (Genentech) and Novartis. The full length therapeutic antibody Avastin recorded sales of US$ 5.6 bln in the year 2011 and is mainly being used for treatment of colorectal, renal cell and non-small cell lung cancer (EU and US) as well as of breast cancer (EU) and glioblastoma (US). The humanized antibody fragment Lucentis marketed by Novartis and Roche/Genentech (USA) generated 2011 sales of US$ 3.67 bln. Approved indications of Lucentis include wet age-related macular degeneration (AMD), diabetic macular edema (DME) and Macular edema following retinal vein occlusion (RVO).
The next generation of anti-VEGF antibodies is lead by the fusion protein aflibercept with recent first approvals in oncology and ophthalmology and a number of other improved molecules including antibodies targeting the receptors of VEGF. Bispecific antibodies targeting VEGF and a second angiogenic target are strongly emerging, but still in earlier phases.
Patents covering Avastion and Lucentis are going to expire in the US and EU over the next couple of years and are paving the way for biosimilar antibodies. The first Avastin biosimilars are already in clinical trials and the pipeline has at least further ten biosimilars in preparation for further development.
A similar pattern of development activities can be seen for ranibizumab: next generation, improved molecules, delivery solutions, extension of indications and biosimilar molecules.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Key Topics Covered
1. Bevacizumab Biosimilars and Biosuperiors
Marketed VEGF Antibody: Avastin Pipeline
Next Generation Avastin Pipeline
- Anti-VEGF Antibody Pipeline
- Anti-VEGF-R Antibody Pipeline
- Bispecific Anti-VEGF Pipeline
Avastin Biosimilar Pipeline
2. Ranibizumab Biosimilars and Biosuperiors
Marketed VEGF Antibody: Lucentis Pipeline
Next Generation Lucentis Pipeline
Lucentis Biosimilar Pipeline
3. Corporate VEGF/-R Antibodies R&D Pipelines
Examples of Companies Mentioned
- Bayer HealthCare Pharmaceuticals
- Boehringer Ingelheim
- Clearside Biomedical
- Eli Lilly (ImClone)
- IBC Generium
- Natco Pharma
- Novartis (Alcon)
- Roche (Genentech, Chugai)
- Simcere Pharmaceutical
- Zenotech Laboratories
For more information visit http://www.researchandmarkets.com/research/8gwkqg/competitor
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here